Mode
Text Size
Log in / Sign up
Phase 4 N=50 Randomized Double-blind Treatment

Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks

Hip Arthroplasty · Hip Pain

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcome: Primary: Percent Change From Baseline in Quadriceps Femoris Maximum Voluntary Isometric Contraction (MVIC) — 64.1; 68 percentage change from baseline of MVIC

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
0.1% Ropivacaine (Drug); 0.4% Ropivacaine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of California, San Diego
Primary completion
Jun 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change From Baseline in Quadriceps Femoris Maximum Voluntary Isometric Contraction (MVIC)
64.1; 68
SECONDARY
Ambulation 100-foot Walking Test
4.6; 5.3; 4.0; 3.6
SECONDARY
Total Ambulation
136; 119; 223; 214
SECONDARY
Percent Change From Baseline in Hip Flexion
69; 67; 75; 78
SECONDARY
Mean Resting Pain
3.2; 3.2
SECONDARY
Average Dynamic Pain
3.8; 3.8; 3.2; 2.9
SECONDARY
Worst Dynamic Pain
6.2; 6.5; 4.3; 5.0

Summary

This is a research study to determine if the concentration of local anesthetic through a catheter next to the nerves that go to the hip that is undergoing surgery, affects muscle strength and sense of touch experienced after surgery. This study is looking at the varying concentrations of local anesthetic placed through the catheter.

Eligibility Criteria

Inclusion Criteria

  • Primary, unilateral hip arthroplasty
  • age greater than or equal to 18 years
  • postoperative analgesic plan includes perineural local anesthetic infusion

Exclusion Criteria

  • morbid obesity as defined by a body mass index greater than 40
  • chronic high dose opioid use
  • history of opioid abuse
  • neuro-muscular deficit of the ipsilateral femoral nerve and/or quadriceps muscle
  • vulnerable populations i.e., children, pregnant women, or prisoners
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00912873). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search